Literature DB >> 22027994

CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy.

M Cecilia Ljungberg1, Yousuf O Ali, Jie Zhu, Chia-Shan Wu, Kazuhiro Oka, R Grace Zhai, Hui-Chen Lu.   

Abstract

Tauopathies, characterized by neurofibrillary tangles (NFTs) of phosphorylated tau proteins, are a group of neurodegenerative diseases, including frontotemporal dementia and both sporadic and familial Alzheimer's disease. Forebrain-specific over-expression of human tau(P301L), a mutation associated with frontotemporal dementia with parkinsonism linked to chromosome 17, in rTg4510 mice results in the formation of NFTs, learning and memory impairment and massive neuronal death. Here, we show that the mRNA and protein levels of NMNAT2 (nicotinamide mononucleotide adenylyltransferase 2), a recently identified survival factor for maintaining neuronal health in peripheral nerves, are reduced in rTg4510 mice prior to the onset of neurodegeneration or cognitive deficits. Two functional cAMP-response elements (CREs) were identified in the nmnat2 promoter region. Both the total amount of phospho-CRE binding protein (CREB) and the pCREB bound to nmnat2 CRE sites in the cortex and the hippocampus of rTg4510 mice are significantly reduced, suggesting that NMNAT2 is a direct target of CREB under physiological conditions and that tau(P301L) overexpression down-regulates CREB-mediated transcription. We found that over-expressing NMNAT2 or its homolog NMNAT1, but not NMNAT3, in rTg4510 hippocampi from 6 weeks of age using recombinant adeno-associated viral vectors significantly reduced neurodegeneration caused by tau(P301L) over-expression at 5 months of age. In summary, our studies strongly support a protective role of NMNAT2 in the mammalian central nervous system. Decreased endogenous NMNAT2 function caused by reduced CREB signaling during pathological insults may be one of underlying mechanisms for neuronal death in tauopathies.
© The Author 2011. Published by Oxford University Press. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22027994      PMCID: PMC3276285          DOI: 10.1093/hmg/ddr492

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  101 in total

Review 1.  Function and regulation of CREB family transcription factors in the nervous system.

Authors:  Bonnie E Lonze; David D Ginty
Journal:  Neuron       Date:  2002-08-15       Impact factor: 17.173

Review 2.  Recombinant adeno-associated viral vectors in the nervous system.

Authors:  Corinna Burger; Kevin Nash; Ronald J Mandel
Journal:  Hum Gene Ther       Date:  2005-07       Impact factor: 5.695

Review 3.  Tau protein pathology in neurodegenerative diseases.

Authors:  M G Spillantini; M Goedert
Journal:  Trends Neurosci       Date:  1998-10       Impact factor: 13.837

4.  The Drosophila cell corpse engulfment receptor Draper mediates glial clearance of severed axons.

Authors:  Jennifer M MacDonald; Margaret G Beach; Ermelinda Porpiglia; Amy E Sheehan; Ryan J Watts; Marc R Freeman
Journal:  Neuron       Date:  2006-06-15       Impact factor: 17.173

5.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues.

Authors:  Xinmin Zhang; Duncan T Odom; Seung-Hoi Koo; Michael D Conkright; Gianluca Canettieri; Jennifer Best; Huaming Chen; Richard Jenner; Elizabeth Herbolsheimer; Elizabeth Jacobsen; Shilpa Kadam; Joseph R Ecker; Beverly Emerson; John B Hogenesch; Terry Unterman; Richard A Young; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

6.  Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve.

Authors:  E R Lunn; V H Perry; M C Brown; H Rosen; S Gordon
Journal:  Eur J Neurosci       Date:  1989       Impact factor: 3.386

7.  S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury.

Authors:  D Kögel; M Peters; H-G König; S M A Hashemi; N T Bui; V Arolt; M Rothermundt; J H M Prehn
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

8.  Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.

Authors:  Virginie Rhein; Xiaomin Song; Andreas Wiesner; Lars M Ittner; Ginette Baysang; Fides Meier; Laurence Ozmen; Horst Bluethmann; Stefan Dröse; Ulrich Brandt; Egemen Savaskan; Christian Czech; Jürgen Götz; Anne Eckert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

9.  Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.

Authors:  Wen-Lang Lin; Jada Lewis; Shu-Hui Yen; Michael Hutton; Dennis W Dickson
Journal:  J Neurocytol       Date:  2003-11

10.  Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau.

Authors:  Sébastien Perreault; Olivier Bousquet; Michel Lauzon; Jacques Paiement; Nicole Leclerc
Journal:  J Neuropathol Exp Neurol       Date:  2009-05       Impact factor: 3.685

View more
  54 in total

1.  Severe biallelic loss-of-function mutations in nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) in two fetuses with fetal akinesia deformation sequence.

Authors:  Marshall Lukacs; Jonathan Gilley; Yi Zhu; Giuseppe Orsomando; Carlo Angeletti; Jiaqi Liu; Xiuna Yang; Joun Park; Robert J Hopkin; Michael P Coleman; R Grace Zhai; Rolf W Stottmann
Journal:  Exp Neurol       Date:  2019-05-25       Impact factor: 5.330

Review 2.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

3.  Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model.

Authors:  Christopher Nishioka; Hsiao-Fang Liang; Barsam Barsamian; Shu-Wei Sun
Journal:  Neuroimage       Date:  2019-01-07       Impact factor: 6.556

Review 4.  NMNAT: It's an NAD+ synthase… It's a chaperone… It's a neuroprotector.

Authors:  Jennifer M Brazill; Chong Li; Yi Zhu; R Grace Zhai
Journal:  Curr Opin Genet Dev       Date:  2017-04-23       Impact factor: 5.578

5.  DLK Activation Synergizes with Mitochondrial Dysfunction to Downregulate Axon Survival Factors and Promote SARM1-Dependent Axon Degeneration.

Authors:  Daniel W Summers; Erin Frey; Lauren J Walker; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  Mol Neurobiol       Date:  2019-11-07       Impact factor: 5.590

Review 6.  Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury.

Authors:  Katrina Owens; Ji H Park; Rosemary Schuh; Tibor Kristian
Journal:  Transl Stroke Res       Date:  2013-08-10       Impact factor: 6.829

7.  The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Authors:  Lu-Zhe Pan; Dae-Gyun Ahn; Tanveer Sharif; Derek Clements; Shashi A Gujar; Patrick W K Lee
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

8.  The role of autophagy in Nmnat-mediated protection against hypoxia-induced dendrite degeneration.

Authors:  Yuhui Wen; R Grace Zhai; Michael D Kim
Journal:  Mol Cell Neurosci       Date:  2012-11-15       Impact factor: 4.314

9.  NAD+ salvage pathway proteins suppress proteotoxicity in yeast models of neurodegeneration by promoting the clearance of misfolded/oligomerized proteins.

Authors:  Alejandro Ocampo; Jingjing Liu; Antoni Barrientos
Journal:  Hum Mol Genet       Date:  2013-01-18       Impact factor: 6.150

10.  Lack of nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2): consequences for mouse bladder development and function.

Authors:  Amy N Hicks; Lysanne Campeau; David Burmeister; Colin E Bishop; Karl-Erik Andersson
Journal:  Neurourol Urodyn       Date:  2013-01-31       Impact factor: 2.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.